In last trading session, IO Biotech Inc (NASDAQ:IOBT) saw 0.64 million shares changing hands with its beta currently measuring 0.64. Company’s recent per share price level of $0.84 trading at -$0.06 or -5.71% at ring of the bell on the day assigns it a market valuation of $55.60M. That closing price of IOBT’s stock is at a discount of -150.0% from its 52-week high price of $2.10 and is indicating a premium of 2.38% from its 52-week low price of $0.82. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.38 million shares which gives us an average trading volume of 185.84K if we extend that period to 3-months.
For IO Biotech Inc (IOBT), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.33. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.29 in the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
IO Biotech Inc (NASDAQ:IOBT) trade information
Upright in the red during last session for losing -5.71%, in the last five days IOBT remained trading in the red while hitting it’s week-highest on Friday, 08/30/24 when the stock touched $0.84 price level, adding 46.05% to its value on the day. IO Biotech Inc’s shares saw a change of -55.11% in year-to-date performance and have moved -45.19% in past 5-day. IO Biotech Inc (NASDAQ:IOBT) showed a performance of -36.06% in past 30-days. Number of shares sold short was 75487.0 shares which calculate 0.39 days to cover the short interests.
IO Biotech Inc (IOBT) estimates and forecasts
Statistics highlight that IO Biotech Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -52.32% of value to its shares in past 6 months, showing an annual growth rate of 39.39% while that of industry is 17.90. Apart from that, the company came raising its revenue forecast for fiscal year 2024.
3.0 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of nan for the same. And 3.0 analysts are in estimates of company making revenue of nan in the next quarter. Company posted nan and nan of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -46.06% during past 5 years.
IO Biotech Inc (NASDAQ:IOBT)’s Major holders
Insiders are in possession of 0.24% of company’s total shares while institution are holding 77.30 percent of that, with stock having share float percentage of 77.48%. Investors also watch the number of corporate investors in a company very closely, which is 77.30% institutions for IO Biotech Inc that are currently holding shares of the company. VIVO CAPITAL, LLC is the top institutional holder at IOBT for having 6.17 million shares of worth $7.22 million. And as of 2024-06-30, it was holding 9.3706 of the company’s outstanding shares.
The second largest institutional holder is NOVO HOLDINGS A/S, which was holding about 4.43 million shares on 2024-06-30. The number of shares represents firm’s hold over 6.7234 of outstanding shares, having a total worth of $5.18 million.
On the other hand, Fidelity Select Portfolios – Biotechnology and Bridgeway Funds Inc-Ultra Small Company Market Fund are the top two Mutual Funds which own company’s shares. As of Jul 31, 2024 , the former fund manager was holding 314.6 shares of worth $0.27 million or 0.48% of the total outstanding shares. The later fund manager was in possession of 124.0 shares on Jun 30, 2024 , making its stake of worth around $0.1 million in the company or a holder of 0.19% of company’s stock.
